Edgestream Partners L.P. Makes New $5.59 Million Investment in TG Therapeutics, Inc. $TGTX

Edgestream Partners L.P. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the first quarter, HoldingsChannel.com reports. The firm acquired 168,351 shares of the biopharmaceutical company’s stock, valued at approximately $5,593,000.

Other hedge funds also recently modified their holdings of the company. Danske Bank A S bought a new stake in TG Therapeutics during the third quarter worth about $25,000. EverSource Wealth Advisors LLC grew its stake in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. grew its stake in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC increased its position in shares of TG Therapeutics by 172.4% during the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics during the 4th quarter worth approximately $52,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 0.1%

Shares of TGTX stock opened at $53.53 on Friday. The stock has a market cap of $8.19 billion, a P/E ratio of 18.72, a price-to-earnings-growth ratio of 1.34 and a beta of 1.60. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $59.30. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock has a 50 day simple moving average of $50.21 and a 200 day simple moving average of $38.77.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.TG Therapeutics’s revenue was up 69.5% on a year-over-year basis. During the same quarter last year, the business earned $0.03 EPS. On average, research analysts predict that TG Therapeutics, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TGTX shares. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Bank of America boosted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. B. Riley Financial upped their price target on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Finally, HC Wainwright raised their price target on shares of TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, TG Therapeutics has an average rating of “Hold” and an average price target of $58.50.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.